Individualizing tapering antipsychotic schemes considering D2 blockade dynamics

J Psychopharmacol. 2021 Sep;35(9):1161-1162. doi: 10.1177/02698811211000780. Epub 2021 Jul 27.

Authors

Carlos G Costardi¹, Ary Gadelha², Rodrigo A Bressan³

Affiliations

¹ Laboratório Interdisciplinar de Neurociências Clínicas (LiNC), Departamento de Psiquiatria, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
² Programa de Esquizofrenia (PROESQ), Departamento de Psiquiatria, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
³ Instituto Ame Sua Mente, São Paulo, Brazil.

PMID: 34313143
DOI: 10.1177/02698811211000780

No abstract available

Publication types

Letter

MeSH terms

Antipsychotic Agents / administration & dosage*
Antipsychotic Agents / adverse effects
Dopamine D2 Receptor Antagonists / administration & dosage
Dopamine D2 Receptor Antagonists / adverse effects
Dose-Response Relationship, Drug
Drug Tapering / methods*
Humans
Practice Guidelines as Topic
Receptors, Dopamine D2 / drug effects
Schizophrenia / drug therapy*

Substances

Antipsychotic Agents
Dopamine D2 Receptor Antagonists
Receptors, Dopamine D2